PartnershipApr 28, 2026, 08:04 AM
EBS inks $34.5M deal for JE vaccine mfg & US govt distribution
AI Summary
Emergent BioSolutions (EBS) announced a $34.5 million agreement with Substipharm Biologics for the manufacturing of drug substance for its Japanese Encephalitis (JE) vaccine, IMOJEV®, at Emergent's Canton, Massachusetts facility. Under the deal, Emergent will also serve as the exclusive distributor of the vaccine to the U.S. government, pending potential FDA approval. The Canton facility recently received a "No Action Indicated" status from the FDA, reflecting compliance, and Emergent has begun scale-up efforts and plans to hire additional employees. This partnership leverages Emergent's specialized capabilities and supports the U.S. government's preparedness needs.
Key Highlights
- EBS entered a $34.5M agreement with Substipharm Biologics for Japanese Encephalitis (JE) vaccine manufacturing.
- Emergent will be the exclusive distributor of IMOJEV® to the U.S. government, pending FDA approval.
- Emergent's Canton, MA facility will manufacture the IMOJEV® drug substance.
- The Canton facility received a "No Action Indicated" FDA status classification in February 2026.
- Emergent has begun scale-up efforts at the Canton facility and plans to hire additional employees.